UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 86

Sortiert nach

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2023-03, Vol.401 (10379), p.821-832

2023

Volltextzugriff (PDF)

Radium-223 dichloride: a new paradigm in the treatment of prostate cancer

Expert review of anticancer therapy, 2015-03, Vol.15 (3), p.339-348

2015

Volltextzugriff (PDF)

Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

Oral oncology, 2022-11, Vol.134, p.106087-106087, Article 106087

2022

Volltextzugriff (PDF)

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide

The Prostate, 2023-03, Vol.83 (4), p.376-384

2023

Volltextzugriff (PDF)

Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

Current Oncology Reports, 2016-12, Vol.18 (12), p.72-72, Article 72

2016

Volltextzugriff (PDF)

Prostate cancer perspectives after chaarted: Optimizing treatment sequence

Critical reviews in oncology/hematology, 2016-11, Vol.107, p.119-127

2016

Volltextzugriff (PDF)

Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor

Cancer treatment reviews, 2015-03, Vol.41 (3), p.247-253

2015

Volltextzugriff (PDF)

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma

Cancer chemotherapy and pharmacology, 2014-06, Vol.73 (6), p.1095-1107

2014

Volltextzugriff (PDF)

PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study

Lung cancer management, 2021-12, Vol.10 (4)

2021

Volltextzugriff (PDF)

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

Lung cancer (Amsterdam, Netherlands), 2020-12, Vol.150, p.62-69

2020

Volltextzugriff (PDF)

Inorganic nanoparticles in diagnosis and treatment of breast cancer

Journal of biological inorganic chemistry, 2018-05, Vol.23 (3), p.331-345

2018

Volltextzugriff (PDF)

Proteomics as a Complementary Technique to Characterize Bladder Cancer

Cancers, 2021-11, Vol.13 (21), p.5537

2021

Volltextzugriff (PDF)

Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma

Clinical genitourinary cancer, 2019-06, Vol.17 (3), p.e526-e533

2019

Volltextzugriff (PDF)

Phase II study of irinotecan as first‐line chemotherapy for patients with advanced colorectal carcinoma

Cancer, 2001-02, Vol.91 (4), p.704-711

2001

Volltextzugriff (PDF)

Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Cancers, 2022-02, Vol.14 (4), p.1087

2022

Volltextzugriff (PDF)

Radium-223 for mCRPC, a real-world experience study from 7 Galician medical centers

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.96-96

2023

Volltextzugriff (PDF)

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Lung cancer (Amsterdam, Netherlands), 2024-08, Vol.194, p.107865, Article 107865

2024

Volltextzugriff (PDF)

Efficacy of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer (MIBC) (SOGUG-2017-A-IEC(VEJ)-4)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS601-TPS601

2020

Volltextzugriff (PDF)

Detection of Circulating Serum Protein Biomarkers of Non-Muscle Invasive Bladder Cancer after Protein Corona-Silver Nanoparticles Analysis by SWATH-MS

Nanomaterials (Basel, Switzerland), 2021-09, Vol.11 (9), p.2384

2021

Volltextzugriff (PDF)

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

Anti-cancer drugs, 2012-02, Vol.23 (2), p.239-246

2012

Volltextzugriff (PDF)

Identification of a Profile of Neutrophil-Derived Granule Proteins in the Surface of Gold Nanoparticles after Their Interaction with Human Breast Cancer Sera

Nanomaterials (Basel, Switzerland), 2020-06, Vol.10 (6), p.1223

2020

Volltextzugriff (PDF)

Third and successive–lines of chemotherapy in NSCLC patients without therapeutic targets: Experience of the Grupo Gallego de Cáncer de Pulmón

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20579-e20579

2019

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(86)

Publikationsform

Artikel
(86)

Sprache

Englisch
(86)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(31)
Oncology
(22)
Humans
(16)
Biomarkers
(9)
Male
(8)
Cancer Therapies
(7)
Chemotherapy
(7)
Female
(7)
Prognosis
(7)
Nanoparticles
(6)
Patients
(6)
Proteomics
(6)
Adult
(5)
Aged
(5)
Middle Aged
(5)
Antineoplastic Agents - Therapeutic Use
(4)
Biochemistry & Molecular Biology
(4)
Bladder Cancer
(4)
Breast Cancer
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(49)
Cancers
(3)
Journal Of Proteomics
(3)
Lung Cancer
(3)
Anti-Cancer Drugs
(2)
Nanomaterials
(2)
The Lancet
(2)
Annals Of Oncology
(1)
Cancer
(1)
Cancer Chemotherapy And Pharmacology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Radium-223 dichloride: a new paradigm in the treatment of prostate cancer

Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

Prostate cancer perspectives after chaarted: Optimizing treatment sequence

Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma

PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

Inorganic nanoparticles in diagnosis and treatment of breast cancer

Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial

Proteomics as a Complementary Technique to Characterize Bladder Cancer

Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma

Phase II study of irinotecan as first‐line chemotherapy for patients with advanced colorectal carcinoma

Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Radium-223 for mCRPC, a real-world experience study from 7 Galician medical centers

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Efficacy of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer (MIBC) (SOGUG-2017-A-IEC(VEJ)-4)

Detection of Circulating Serum Protein Biomarkers of Non-Muscle Invasive Bladder Cancer after Protein Corona-Silver Nanoparticles Analysis by SWATH-MS

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

Identification of a Profile of Neutrophil-Derived Granule Proteins in the Surface of Gold Nanoparticles after Their Interaction with Human Breast Cancer Sera

Third and successive–lines of chemotherapy in NSCLC patients without therapeutic targets: Experience of the Grupo Gallego de Cáncer de Pulmón

Suchergebnisse filtern